1-4 of 4
Jeanmarie Guenot
Close
Sort by
Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 834.
https://doi.org/10.1182/blood-2019-129042
Published: 2019
Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MDPhD, Gail J. Roboz, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Sangmin Lee, MD, Michael P. Rettig, PhD, Tae H. Han, PhD, Jeanmarie Guenot, PhD, Eric J. Feldman, MD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1455.
https://doi.org/10.1182/blood-2018-99-111529
Published: 2018
Journal Articles

AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia

Linda G Eissenberg, PhD, Julie Ritchey, Michael P. Rettig, PhD, Judith A. Fox, PhD, Jeanmarie Guenot, PhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2727.
https://doi.org/10.1182/blood-2018-99-118573
Published: 2018
Journal Articles

Immunodepletion of MDSC By AMV564, a Novel Tetravalent Bispecific CD33/CD3 T Cell Engager Restores Immune Homeostasis in MDS in Vitro

Pingyan Cheng, MD, Erika Eksioglu, PhD MS, Xianghong Chen, PhD, Max Wei, Jeanmarie Guenot, Judy Fox, Alan F List, MD, Sheng Wei, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 51.
https://doi.org/10.1182/blood.V130.Suppl_1.51.51
Published: 2017